Hypereosinophilic syndrome variants: Diagnostic and therapeutic considerations

Haematologica

Volumn 94, Issue 9, 2009, Pages 1188-1193

  Roufosse, Florence ^a,b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CORTICOSTEROID; FIP 1 LIKE 1 PROTEIN; IMATINIB; MEPOLIZUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DIAGNOSTIC PROCEDURE; EDITORIAL; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPEREOSINOPHILIC SYNDROME; LYMPHOCYTE VARIANT HYPEREOSINOPHILIC SYNDROME; PATHOGENESIS; T CELL MEDIATED HYPEREOSINOPHILIC SYNDROME; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

HUMANS; HYPEREOSINOPHILIC SYNDROME;

EID: 70349107991     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.010421     Document Type: Editorial

References (29)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1-27.
2. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006;117:1292-1302
3. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214 (Pubitemid 36359296)
4. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-1578 (Pubitemid 34621126)
5. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003;100:7830-7835 (Pubitemid 36760055)
6. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038-3045 (Pubitemid 39507117)
7. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-4666 (Pubitemid 36857718)
8. Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA- positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007;110:3552-3556 (Pubitemid 350159620)
9. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008;143:707-715
10. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994;330:535-538 (Pubitemid 24058956)
11. Roufosse F, Schandene L, Sibille C, Willard-Gallo K, Kennes B, Efira A, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000;109:540-548 (Pubitemid 30415180)
12. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:389-413.
13. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341:1112-1120 (Pubitemid 29466223)
14. Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, Majewski M, Kyrcz-Krzemien S. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica 2009;94:1236-1241
15. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, et al. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res 2007;31:691-694
16. Galimberti S, Ciabatti E, Ottimo F, Rossi A, Trombi L, Carulli G, et al. Cell clonality in hypereosinophilic syndrome: what pathogenetic role? Clin Exp Rheumatol 2007;25:17-22.
17. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1- PDGFRA fusion gene in eosinophilia- associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007;21:1183-1188 (Pubitemid 46831806)
18. McPherson T, Cowen EW, McBurney E, Klion AD. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis. Br J Dermatol 2006;155:824-826 (Pubitemid 44352566)
19. de Lavareille A, Roufosse F, Schandene L, Stordeur P, Cogan E, Goldman M. Clonal Th2 cells associated with chronic hypereosinophilia: TARC-induced CCR4 downregulation in vivo. Eur J Immunol 2001;31:1037-1046
20. de Lavareille A, Roufosse F, Schmid-Grendelmeier P, Roumier AS, Schandene L, Cogan E, et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 2002;110:476-479
21. Bruggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, et al. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 2007;21:215-221 (Pubitemid 46158112)
22. Wang HB, Ghiran I, Matthaei K, Weller PF. Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells. J Immunol 2007;179:7585-7592
23. Jacobsen EA, Ochkur SI, Pero RS, Taranova AG, Protheroe CA, Colbert DC, et al. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J Exp Med 2008;205:699-710.
24. Willard-Gallo KE, Badran BM, Ravoet M, Zerghe A, Burny A, Martiat P, et al. Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome. Exp Hematol 2005;33:1147-1159 (Pubitemid 41416963)
25. Ravoet M, Sibille C, Roufosse F, Duvillier H, Sotiriou C, Schandene L, et al. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica 2005;90:753-765 (Pubitemid 40897217)
26. Simon HU, Yousefi S, Dommann-Scherrer CC, Zimmermann DR, Bauer S, Barandun J, et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183:1071-1082 (Pubitemid 3041981)
27. Ravoet M, Sibille C, Gu C, Libin M, Haibe-Kains B, Sotiriou C, et al. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood. 2009 Jul 16. [Epub ahead of print]
28. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215-1228
29. Bergua JM, Prieto-Pliego E, Roman-Barbera A, Garcia- Toron J, Gomez-Barrado JJ, Marcos G, et al. Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation. Ann Hematol 2008;87:937-938